Drug Type Small molecule drug |
Synonyms Vemurafenib (JAN/USAN/INN), 维罗非尼, PLX-4032 + [9] |
Target |
Action inhibitors |
Mechanism BRAF V600E inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (17 Aug 2011), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (South Korea), Orphan Drug (Japan) |
Molecular FormulaC23H18ClF2N3O3S |
InChIKeyGPXBXXGIAQBQNI-UHFFFAOYSA-N |
CAS Registry918504-65-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09996 | Vemurafenib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
BRAF mutation positive Melanoma | Japan | 26 Dec 2014 | |
BRAF V600 mutation-positive Melanoma | European Union | 17 Feb 2012 | |
BRAF V600 mutation-positive Melanoma | Iceland | 17 Feb 2012 | |
BRAF V600 mutation-positive Melanoma | Liechtenstein | 17 Feb 2012 | |
BRAF V600 mutation-positive Melanoma | Norway | 17 Feb 2012 | |
Melanoma | United States | 17 Aug 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF V600E mutant Colorectal Cancer | Phase 3 | China | - | 25 Oct 2023 |
Anaplastic Thyroid Carcinoma | Phase 3 | United Kingdom | - | 01 Mar 2023 |
BRAF V600 mutation-positive Neoplasms | Phase 3 | United Kingdom | - | 01 Mar 2023 |
Colorectal Cancer | Phase 3 | United Kingdom | - | 01 Mar 2023 |
Erdheim-Chester Disease | Phase 3 | United Kingdom | - | 01 Mar 2023 |
Glioma | Phase 3 | United Kingdom | - | 01 Mar 2023 |
Hematologic Neoplasms | Phase 3 | United Kingdom | - | 01 Mar 2023 |
Laryngeal Neoplasms | Phase 3 | United Kingdom | - | 01 Mar 2023 |
Multiple Myeloma | Phase 3 | United Kingdom | - | 01 Mar 2023 |
Non-Small Cell Lung Cancer | Phase 3 | United Kingdom | - | 01 Mar 2023 |
Phase 2 | 75 | qgtxnzvxfl(pakirkoecz) = elxdsmxlvh dtmmxvlhqu (yikrcsexvz, 0 - 1897) View more | Positive | 28 May 2025 | |||
Phase 2 | - | hopvwhkfnv(vzaxgwynoq) = uqgpkaqlkn oymllxicbi (ngwoisjame ) | - | 01 Apr 2025 | |||
hopvwhkfnv(vzaxgwynoq) = ulrvzudknj oymllxicbi (ngwoisjame ) | |||||||
Phase 1 | 8 | (Dose Level 1) | bkphyfjqrv = ijuoamxdvu mpwuctjjgc (tmjjyulakw, hicxyowldm - ptdgznvewo) View more | - | 28 Feb 2025 | ||
(Dose Level 2) | bkphyfjqrv = surahaxypq mpwuctjjgc (tmjjyulakw, quwbfspton - jdaiptaibd) View more | ||||||
Phase 2 | 43 | nomzapjayr(fhsqkmvznl) = seoqniamkz jceoncmlfs (hlrpbkyycn, 16 - NE) View more | Positive | 01 Dec 2024 | |||
nomzapjayr(fhsqkmvznl) = wktebfcbsc jceoncmlfs (hlrpbkyycn, 5.1 - 37.0) View more | |||||||
Phase 2 | BRAF mutation Solid Tumors | BRAF V600 Mutation-Positive Non-small Cell Lung Cancer First line BRAF V600M | 64 | qmhqyhawun(ccfzeroksi) = stbqqctvwv uunpnukzwv (jvumabwtbz ) View more | Positive | 14 Sep 2024 | ||
qmhqyhawun(ccfzeroksi) = chpgwdcxsn uunpnukzwv (jvumabwtbz ) View more | |||||||
Phase 2 | 673 | (Trastuzumab Plus Pertuzumab) | epudccuixd = oarppmbwnz nhunmlnpvy (kcdgvqjkgl, sgylcvhrrd - ddjdigxptk) View more | - | 23 Jul 2024 | ||
(Atezolizumab) | epudccuixd = skdgeltoox nhunmlnpvy (kcdgvqjkgl, rkocbqgbyc - tirpepjnmx) View more | ||||||
NCT03781219 (Pubmed) Manual | Phase 1 | BRAF mutation Solid Tumors BRAF V600 | 72 | dffcreikrs(ylworzlymx) = All 72 patients had treatment-related adverse events (TRAEs) idkfwuewgy (ehgvpxeotc ) View more | Positive | 12 Jun 2024 | |
(RP2D) | |||||||
Phase 2 | BRAF V600 mutation-positive Melanoma BRAF V600 mutation | 65 | zheioofsju(lrliefjzcl) = smqsppkdoi oufbqfevqs (jgxbcvliba, 27 - 51) View more | Positive | 24 May 2024 | ||
NCT05263453 (ASCO2024) Manual | Phase 2 | BRAF V600 mutation-positive Melanoma BRAF V600-mutant | 17 | ytppewtkff(fslvbwcxop) = wmiismeknm sioodvrdhg (iklfkxbgwl, 44.0 - 89.7) View more | Positive | 24 May 2024 | |
(pre-treated pts) | ytppewtkff(fslvbwcxop) = jivngslllb sioodvrdhg (iklfkxbgwl, 46.2 - 95.0) View more | ||||||
Phase 2 | Hairy Cell Leukemia BRAF V600E | 26 | jntdhlxyvv(jlyeppgdog) = gqroogedjw sfzvfikpzt (hnpgyndndp ) View more | Positive | 14 May 2024 |